Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010689:Phlebitis / Q000139:chemically induced
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene